References
- Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med 2012; 367:1035-44; PMID:22970946; https://doi.org/https://doi.org/10.1056/NEJMra1204699
- Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006; 4:272-82; PMID:16541135; https://doi.org/https://doi.org/10.1038/nrmicro1385
- Choh LC, Ong GH, Vellasamy KM, Kalaiselvam K, Kang WT, Al-Maleki AR, Mariappan V, Vadivelu J. Burkholderia vaccines: are we moving forward? Front Cell Infect Microbiol 2013; 3:5; PMID:23386999; https://doi.org/https://doi.org/10.3389/fcimb.2013.00005
- Aschenbroich SA, Lafontaine ER, Hogan RJ. Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches. Expert Rev Vaccines 2016; 15:1163-81; PMID:27010618; https://doi.org/https://doi.org/10.1586/14760584.2016.1170598
- Sarkar-Tyson M, Titball RW. Progress toward development of vaccines against melioidosis: A review. Clin Ther 2010; 32:1437-45; PMID:20728758; https://doi.org/https://doi.org/10.1016/j.clinthera.2010.07.020
- Lee SH, Danishmalik SN, Sin JI. DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother 2015; 11:1889-900; PMID:25984993; https://doi.org/https://doi.org/10.1080/21645515.2015.1035502
- Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011; 53:296-302; PMID:21765081; https://doi.org/https://doi.org/10.1093/cid/cir334
- Patel N, Conejero L, De Reynal M, Easton A, Bancroft GJ, Titball RW. Development of vaccines against burkholderia pseudomallei. Front Microbiol 2011; 2:198; PMID:21991263; https://doi.org/https://doi.org/10.3389/fmicb.2011.00198
- Chen YS, Hsiao YS, Lin HH, Yen CM, Chen SC, Chen YL. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine 2006; 24:750-8; PMID:16169637; https://doi.org/https://doi.org/10.1016/j.vaccine.2005.08.069
- Chen YS, Hsiao YS, Lin HH, Liu Y, Chen YL. CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect Immun 2006; 74:1699-705; PMID:16495541; https://doi.org/https://doi.org/10.1128/IAI.74.3.1699-1705.2006
- Lankelma JM, Wagemakers A, Birnie E, Haak BW, Trentelman JJ, Weehuizen TA, Ersöz J, Roelofs JJTH, Hovius JW, Wiersinga WJ, et al. Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application. Virulence 2017; 1-12; PMID:28323523; https://doi.org/https://doi.org/10.1080/21505594.2017.1307485
- Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GC, White LJ, Day NP, Titball RW. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis 2012; 6:e1488; PMID:22303489; https://doi.org/https://doi.org/10.1371/journal.pntd.0001488
- Xu Y, Yuen PW, Lam JK. Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics 2014; 6:378-415; PMID:25014738; https://doi.org/https://doi.org/10.3390/pharmaceutics6030378
- Regnstrom K, Ragnarsson EG, Koping-Hoggard M, Torstensson E, Nyblom H, Artursson P. PEI - a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice. Gene Ther 2003; 10:1575-83; PMID:12907949; https://doi.org/https://doi.org/10.1038/sj.gt.3302054
- Meleshko AN, Petrovskaya NA, Savelyeva N, Vashkevich KP, Doronina SN, Sachivko NV. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma. Hum Vaccin Immunother 2017:1-6; PMID:28272989; https://doi.org/https://doi.org/10.1080/21645515.2017.1285477